ANI Pharma director sells shares, gets stock grant

ANI Pharmaceuticals director Thomas Haughey reported both a stock grant and a share sale.

Rhea-AI Filing Summary

ANI Pharmaceuticals director Thomas Haughey reported both a stock grant and a share sale. On May 21, 2026, he acquired 4,357 shares of Common Stock as a restricted stock award that will vest in full on May 21, 2027. On June 8, 2026, he sold 2,000 Common Stock shares in an open-market transaction at $80.88 per share under a pre-arranged Rule 10b5-1 trading plan adopted on March 9, 2026. After these transactions, he directly holds 38,878 Common Stock shares.

Insider Trade Summary 10b5-1

Net Seller: 2,000 shares

Net Sell 2 txns

Insider HAUGHEY THOMAS

Role Director

Sold 2,000 shs ($162K)

Type	Security	Shares	Price	Value
Sale	Common Stock	2,000	$80.88	$162K
Grant/Award	Common Stock	4,357	$0.00	$0.00

Holdings After Transaction: Common Stock — 38,878 shares (Direct)

Footnotes (2)

1. F1. Represents a restricted stock award that will vest in full on May 21, 2027.
2. F2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 9, 2026.

Key Figures

Open-market sale: 2,000 shares at $80.88/share Restricted stock award: 4,357 shares Post-transaction holdings: 38,878 shares +2 more

5 metrics

Open-market sale 2,000 shares at $80.88/share Common Stock sale on June 8, 2026

Restricted stock award 4,357 shares Granted May 21, 2026; vests May 21, 2027

Post-transaction holdings 38,878 shares Common Stock held directly after reported transactions

Net buy/sell shares -2,000 shares Form 4 transaction summary net-buy-sell direction

Rule 10b5-1 plan adoption date March 9, 2026 Plan governing the June 8, 2026 sale

Key Terms

restricted stock award, Rule 10b5-1 trading plan, open-market sale, Common Stock

4 terms

restricted stock award financial

"Represents a restricted stock award that will vest in full on May 21, 2027."

A restricted stock award is company shares given to an employee or executive that cannot be sold or fully owned until certain conditions—like staying with the company for a set time or hitting performance targets—are met. Think of it as a gift that only becomes yours after you fulfill specific obligations; for investors, these awards matter because they can increase the total shares outstanding when they vest, reveal how management is being paid and motivated, and create potential selling pressure when restrictions lift.

Rule 10b5-1 trading plan regulatory

"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open-market sale financial

"transaction_action: "open-market sale" for the 2,000-share transaction at $80.88"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Common Stock financial

"security_title: "Common Stock" for both the grant and the sale"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did ANI Pharmaceuticals (ANIP) director Thomas Haughey report?

Thomas Haughey reported a restricted stock grant and a small share sale. He received 4,357 Common Stock shares as a restricted award, then sold 2,000 shares at $80.88 each, ending with 38,878 shares held directly.

How many ANI Pharmaceuticals (ANIP) shares did Thomas Haughey sell and at what price?

He sold 2,000 shares of ANI Pharmaceuticals Common Stock at $80.88 per share. The sale occurred on June 8, 2026, as an open-market transaction reported under transaction code “S” for a sale in the market.

What stock award did Thomas Haughey receive from ANI Pharmaceuticals (ANIP)?

He received a restricted stock award of 4,357 Common Stock shares. The award was granted on May 21, 2026 and is scheduled to vest in full on May 21, 2027, assuming vesting conditions are satisfied.

How many ANI Pharmaceuticals (ANIP) shares does Thomas Haughey hold after these transactions?

After the reported transactions, Thomas Haughey directly holds 38,878 shares of ANI Pharmaceuticals Common Stock. This figure reflects the combination of the 4,357-share restricted stock grant and the subsequent 2,000-share open-market sale.

Was Thomas Haughey’s ANI Pharmaceuticals (ANIP) share sale part of a trading plan?

Yes, the sale was executed under a Rule 10b5-1 trading plan. A footnote states the trades were made pursuant to a plan he adopted on March 9, 2026, indicating the sale was pre-arranged.

When will Thomas Haughey’s restricted ANI Pharmaceuticals (ANIP) shares vest?

His 4,357-share restricted stock award is scheduled to vest in full on May 21, 2027. Until vesting, the shares are subject to the award’s restrictions and conditions as specified by ANI Pharmaceuticals.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/10/2026 - 09:06 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HAUGHEY THOMAS

(Last) (First) (Middle)

C/O ANI PHARMACEUTICALS, INC.

104 CARNEGIE CENTER, SUITE 300

(Street)

PRINCETON NEW JERSEY 08540

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ANI PHARMACEUTICALS INC [ ANIP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/21/2026		A(1)		4,357	A	$0	40,878	D
Common Stock	06/08/2026		S(2)		2,000	D	$80.88	38,878	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a restricted stock award that will vest in full on May 21, 2027.

2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 9, 2026.

Remarks:

	/s/ Thomas Haughey, by attorney-in-fact Meredith W. Cook	06/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)